fbpx

molecules of the month

compound 14d

β2-AMPK activator

in vivo efficacy in diabetic mouse model

scaffold hopping from MK-8722 + opt.

Bioorg. Med. Chem. Lett., 17 November 2022

Shionogi & Co., Osaka, JP

4 mins read

Revisiting AMPK activation with β2-AMPK isoform potency. “Compound 14d” (Shionogi & Co.) is a highly potent, dose-dependent adenosine monophosphate activated protein kinase (AMPK) activator being investigated for its blood-glucose-lowering effects. AMPK became a target-of-interest for the treatment of diabetes due to its role in regulating of glucose and lipid metabolism. Activation of AMPK switches on catabolic pathways, generates ATP, and ultimately inhibits glucogenesis. Indirect AMPK activators increase the AMP-ATP ratio, causing a conformational change and activation upon AMP binding to γ-subunits. AMPK is indirectly activated by one of the most widely prescribed drugs for Type 2 diabetes mellitus, metformin (Glucophage), with more than 92 million prescriptions filled in the US in 2020, making it the third most-commonly prescribed medication. The…


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: